Scleroderma: a treatable disease

Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cleveland Clinic journal of medicine 2003-11, Vol.70 (11), p.954-954
1. Verfasser:	Korn, Joseph H
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive Agents - therapeutic use Bosentan Humans Pulmonary Fibrosis - etiology Scleroderma, Systemic - complications Scleroderma, Systemic - physiopathology Scleroderma, Systemic - therapy Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.
ISSN:	0891-1150 1939-2869
DOI:	10.3949/ccjm.70.11.954